Animal Healthcare Market: Evolving Opportunities with Dechra Pharmaceuticals Plc and Elanco Animal Health Inc. | Technavio
NEW YORK, June 28, 2022 /PRNewswire/ -- The Global Animal Healthcare Market size is expected to grow by USD 7.98 billion at a CAGR of 4.1% during the forecasted period. The report extensively covers animal healthcare market segmentation by product (pharmaceutical, feed additive, and biologicals) and geographic (North America, Europe, APAC, and South America). The animal healthcare market report also offers information on several market vendors, including Bayer AG, C. H. Boehringer Sohn AG & Co. KG, Cadila Healthcare Ltd., Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Heska Corp., Merck & Co. Inc., Norbrook Laboratories Ltd., Virbac SA, and Zoetis Inc. among others.
Read the 120-page report with TOC on "Animal Healthcare Market Analysis Report by Product (Pharmaceutical, Feed additive, and Biologicals) and Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts,2021-2025". Gain competitive intelligence about market leaders.Buy Now!
Key Market Dynamics
The rise in pet ownership is one of the major factors propelling the animal healthcare market's expansion. With nearly two out of every five households having a dog, dogs continue to be the most common form of pet. With almost three in ten families owning a cat, cats were the next most popular form of pet. One of the factors contributing to the rise in pet ownership for companionship and enjoyment is the rise in disposable income. The focus has shifted to improving health services for these animals as people have begun to see these pets as members of the family.
However, contamination of animal source foods is one of the key challenges hindering the animal healthcare market growth
Rare Hemophilia Factors Market by Method and Geography - Forecast and Analysis 2022-2026: The rare hemophilia factors market share is expected to increase to USD 146.76 million from 2021 to 2026, at a CAGR of 7.4%. Download Our Exclusive Sample Report
Obsessive-Compulsive Disorder Drugs Market by Product and Geography - Forecast and Analysis 2022-2026: The obsessive-compulsive disorder drugs market share is expected to increase by USD 266.78 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.55%. Download Our Exclusive Sample Report
Animal Healthcare Market Scope
Report Coverage
Details
Page number
120
Base year
2020
Forecast period
2021-2025
Growth momentum & CAGR
Accelerate at a CAGR of 4.1%
Market growth 2021-2025
$ 7.98 billion
Market structure
Concentrated
YoY growth (%)
3.29
Regional analysis
North America, Europe, APAC, and South America
Performing market contribution
North America at 43%
Key consumer countries
US, China, Germany, and France
Competitive landscape
Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled
Bayer AG, C. H. Boehringer Sohn AG & Co. KG, Cadila Healthcare Ltd., Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Heska Corp., Merck & Co. Inc., Norbrook Laboratories Ltd., Virbac SA, and Zoetis Inc.
Market dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table of Contents
1 Executive Summary
2 Market Landscape
2.1 Market ecosystem
Exhibit 01: Parent market
Exhibit 02: Market characteristics
2.2 Value chain analysis
Exhibit 03: Value chain analysis: Pharmaceuticals market
3 Market Sizing
3.1 Market definition
Exhibit 04: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 05: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021 - 2025
Exhibit 06: Global - Market size and forecast 2021 - 2025 ($ billion)
Exhibit 07: Global market: Year-over-year growth 2021 - 2025 (%)
4 Five Forces Analysis
4.1 Five force summary
Exhibit 08: Five forces analysis 2021 & 2025
4.2 Bargaining power of buyers
Exhibit 09: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 10: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 11: Threat of new entrants
4.5 Threat of substitutes
Exhibit 12: Threat of substitutes
4.6 Threat of rivalry
Exhibit 13: Threat of rivalry
4.7 Market condition
Exhibit 14: Market condition - Five forces 2021
5 Market Segmentation by Product
5.1 Market segments
Exhibit 15: Product - Market share 2021-2025 (%)
5.2 Comparison by Product
Exhibit 16: Comparison by Product
5.3 Pharmaceutical - Market size and forecast 2021-2025
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Information sources
11.4 List of abbreviations
Exhibit 85: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community. Aspire Health experienced a data security incident that may have involved personal and...